Based on clinical phenotypes and according to studies on genetically characterized large cohorts of patients in the United Kingdom, Italy, and China, pathogenic GMPPB mutations are responsible for 2–3% of patients with CMD and 5–7% of patients with LGMD phenotype [32,41,42]. Here, GMPPB is linked to limb-girdle muscular dystrophy.